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The complement system is an efficient anti-microbial effector mechanism. On the
other hand abnormal complement activation is involved in the pathogenesis of
multiple inflammatory and hemolytic diseases. As general inhibition of the complement
system may jeopardize patient health due to increased susceptibility to infections, the
development of pathway-specific complement therapeutics has been a long-lasting
goal over the last decades. In particular, pathogen mimicry has been considered as a
promising approach for the design of selective anti-complement drugs. The C-terminal
domain of staphylococcal superantigen-like protein 7 (SSL7), a protein secreted by
Staphylococcus aureus, was recently found to be a specific inhibitor of the terminal
pathway of the complement system, providing selective inhibition of cell lysis mediated
by the membrane attack complex (MAC). We describe here the selection by phage
display of a humanized single-domain antibody (sdAb) mimicking the C-terminal domain
of SSL7. The antibody, called sdAb_E4, binds complement C5 with an affinity in the low
micromolar range. Furthermore, sdAb_E4 induces selective inhibition of MAC-mediated
lysis, allowing inhibition of red blood cell hemolysis and inhibition of complement
deposition on apopto-necrotic cells, while maintaining efficient bactericidal activity of
the complement terminal pathway. Finally, we present preliminary results indicating that
sdAb_E4 may also be efficient in inhibiting hemolysis of erythrocytes from patients with
paroxysmal nocturnal hemoglobinuria. Our data provide a proof of concept for the
Yatime et al. sdAb_E4 Provides MAC Selective Inhibition
design of a selective MAC inhibitor capable of retaining complement bacteriolytic
activity and this study opens up promising perspectives for the development of an
sdAb_E4-derived therapeutics with application in the treatment of complement-mediated
hemolytic disorders.
Keywords: complement, terminal pathway inhibition, single-domain antibody, pathogen mimicry, hemolysis,
bacteriolysis, paroxysmal nocturnal hemoglobinuria
INTRODUCTION
Upon detection of pathogenic or damaged cells in our body,
the complement cascade of the innate immunity is activated. It
results in a complex chain of proteolytic reactions that ultimately
leads to cleavage of the complement factor C5 and initiation of
the terminal pathway (TP) of the complement system (1, 2). This
cleavage generates the small C5a anaphylatoxin, which triggers
the inflammatory response, and the large C5b fragment, which
then recruits complement proteins C6-C9 to form the membrane
attack complex (MAC) responsible for the lysis of the targeted
cells (3–5). Whereas this process is crucial for host defense upon
pathogenic invasion, it has to be tightly regulated to prevent
aberrant complement activation in non-infected areas and the
ensuing risk of damaging healthy tissues. For this purpose,
host cells express membrane-bound and soluble regulators that
efficiently block the complement cascade (6, 7). Dysregulation
of the complement system, often linked to genetic deficiencies
in these regulatory factors, can lead to various pathological
conditions, including inflammatory and hemolytic disorders that
result from an excessive C5a production and/or the targeting of
host red blood cells by the MAC (1, 4, 8, 9).
A crucial role of complement component C5 has been
demonstrated for several pathologies, e.g., the two life-
threatening hemolytic diseases paroxysmal nocturnal
hemoglobinuria (PNH) (10) and atypical hemolytic uremic
syndrome (aHUS) (11). PNH arises from mutations in the
PIG-A gene in bone marrow stem cells. The resulting matured
cells, including erythrocytes, are deficient in GPI-anchored
proteins and, as a result, lack the MAC inhibitor CD59, which
leads to their destruction by the complement lytic complex
(12, 13). aHUS is characterized by renal-specific thrombotic
microangiopathy which causes massive organ failure and
possibly death without specific treatment (14). C5 activation
also plays a key role in the pathogenesis of aHUS although the
respective contribution of both C5a-mediated inflammation
and uncontrolled MAC activation on endothelial cell surface is
still unclear (11). Due to its critical involvement in PNH and
Abbreviations: aHUS, atypical hemolytic uremic syndrome; AP, alternative
pathway of the complement system; BLI, biolayer interferometry; CP, classical
pathway of the complement system; CVF, cobra venom factor; IPTG,
isopropyl β-D-1-thiogalactopyranoside; MAC, membrane attack complex; MST,
microscale thermophoresis; NHS, normal human serum; sdAb, single-domain
antibody; PNH, paroxysmal nocturnal hemoglobinuria; SEC, size exclusion
chromatography; SSL7, staphylococcal superantigen-like protein 7; TEV, Tobacco
Etch virus; TMB, 3,3′,5,5′-Tetramethylbenzidine; TP, terminal pathway of the
complement system.
aHUS, C5 has been identified as an important drug target for the
treatment of both diseases (15, 16).
Eculizumab, one of the rare complement inhibitors available
on the market, is a monoclonal anti-C5 antibody approved for
the treatment of PNH and aHUS (15). As a general C5 inhibitor,
it efficiently reduces RBC lysis and endothelial damage, thereby
improving considerably the quality of life of the patients (17, 18).
One of themajor drawbacks associated with the administration of
eculizumab is the increased risk of developing a meningococcal
disease since the treated patients lack the lytic MAC for
destruction of these bacteria as well as the C5a-dependent
activation of phagocytic cells (19, 20). Current recommendations
call for vaccination against meningococci prior to eculizumab
treatment, but even in these conditions, neisserial infections
are still occurring, although to a much lower extent and in
a patient-specific manner (19, 21). Thus, more specific C5
inhibitors could be advantageous, in particular inhibitors that
would preserve the TP bactericidal activity. At the moment,
various drug design strategies are being considered to obtain such
molecules (7, 22). In particular, one general approach to obtain
complement inhibitors consists in developing molecules that
mimic the properties of complement evasion proteins secreted
by pathogens in order to prevent complement activation (23).
One example is the secreted staphylococcal superantigen-like
protein 7 (SSL7) which targets C5 (24). Interestingly, whereas
the full-length protein acts as a general C5 inhibitor, thereby
mimicking the mode of action of eculizumab, we found that
the C-terminal domain of the protein behaves as a selective
MAC inhibitor, not only allowing partial C5 cleavage and
subsequent C5a release, but also blocking RBC hemolysis while
maintaining efficient bacteriolysis (25). Hence, if the SSL7 C-
terminal domain (SSL7-CT) was used to block C5 cleavage,
the risk of meningococcal disease could be lower than with
existing anti-C5 therapeutics. As SSL7-CT is of bacterial origin,
it cannot be administered to the human body without risking
the activation of the host immune system. To circumvent this
problem and still take advantage of the appealing properties
of SSL7-CT, we aimed at selecting a single-domain antibody
(sdAb) that would have the same behavior toward C5 as
SSL7-CT.
In this paper, we describe an innovative structure-based
strategy for the selection of anti-C5 sdAbs by phage display
using competitive elution, and we present the evaluation of their
functional properties with respect to inhibition of C5 cleavage
and MAC assembly on erythrocytes, bacteria and endothelial
cells. Our data provide a proof of concept for the selection of an
anti-C5 sdAb that prevents MAC formation on host cells while
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maintaining the bactericidal activity of the terminal pathway of
complement.
MATERIALS AND METHODS
Single-Domain Antibody Selection Using
Phage Display and ELISA
A phage display library composed of human single-domain
antibodies corresponding to the variable domain of the heavy
chain and derived from theHEL4 sdAb (26, 27) by randomization
on all three CDR regions (VH sdAbs, Garvan library, https://
www.sourcebioscience.com/products/life-sciences-research/
clones/artificial-antibody-libraries/human-domain-antibody-
library-dab/) was used for the selection (generous gift from Dr.
Daniel Christ, Garvan Institute, Australia). The selection was
performed according to standard protocols (28) except for the
elution step. Briefly, an immunotube was coated overnight at
4◦C with 75µg/ml of plasma-purified human C5 (29) diluted in
PBS. Residual binding was blocked by incubation with 2% low
fat milk powder in PBS (MPBS). Around 1012 sdAb-displaying
phages from the Garvan library were then added to the tube
and incubated for 2 h at room temperature. After washing off
unbound phages with PBST (0.1 % Tween 20 in PBS), elution
was performed with a 75µg/ml solution of purified SSL7-CT.
The eluted phages were used to infect E. coli TG1 cells in the
log phase. Single colonies were picked and the corresponding
sdAb-phages were rescued for ELISA using the KM13 phage
helper (30).
ELISA was performed in 96-well Nunc MaxiSorp plates
coated with 8µg/ml of human C5. The C5-binding phages were
detected with an anti-M13 antibody conjugated to horseradish
peroxidase (Pharmacia) followed by development with TMB
substrate/sulfuric acid and reading of the absorbance at 450 nm
on a Bio-Rad Model 550 microplate reader. 50ml phage
cultures were prepared for the ELISA-positive clones. Following
precipitation of the phages with PEG (20 % polyethylene glycol
6000 and 2.5M NaCl), the phage particles were resuspended
in PBS and phage dilution series ranging from 1012 to 0.5 ×
109 phages/ml were tested again in the C5-ELISA. The DNA
sequences for the three best clones were obtained from MWG
Eurofins (Germany) (DNA sequences available upon request).
Purification of the VH sdAbs, SSL7-CT and
Complement C5
The sequences coding for the VH sdAbs selected by phage
display were cloned into the Nco I and Xho I restriction sites
of vector pETM11 (EMBL vector collection). A stop codon was
added just before the Xho I site in the reverse primer used for
PCR amplification. The resulting constructs were transformed in
E. coli BL21 (DE3) cells (New England Biolabs). Cells were grown
for 4 h at 37◦C in 2xYT medium supplemented with kanamycin
and protein expression was induced overnight at 18◦C by
the addition of 1mM IPTG. Bacterial pellets were harvested
and sonicated in Buffer A (50mM HEPES pH 7.5, 300mM
NaCl, 30mM imidazole, 1mM PMSF). After clarification by
centrifugation, the supernatant was applied onto a 5mL HisTrap
FF column (GE Healthcare) equilibrated in Buffer A. After high
salt wash (50mM HEPES pH 7.5, 1M NaCl, 30mM imidazole,
1mM PMSF) to remove unspecifically bound proteins, the His6-
tagged proteins were eluted with Buffer B (50mM HEPES pH
7.5, 300mM NaCl, 500mM imidazole, 1mM PMSF). The His6-
tag was then removed by overnight cleavage with in-house
prepared recombinant TEV protease at 4◦C in buffer C (50mM
HEPES pH 7.5, 300mM NaCl, 0.5mM EDTA) followed by
a second run on the HisTrap column. The cleaved proteins
present in the run-through fraction were finally purified by size
exclusion chromatography (SEC) on a 24ml Superdex 75 10/300
GL column (GE Healthcare) equilibrated in Buffer D (20mM
HEPES pH 7.5, 150mM NaCl). Fractions containing the target
protein were analyzed by SDS-PAGE, pooled, flash-frozen in
liquid nitrogen and stored at−80◦C until use.
SSL7 (full-length) and SSL7-CT from strain ATCC 12598 were
purified as previously described (25). Briefly, both proteins were
expressed in E. coli BL21 (DE3) cells. SSL7 was purified using
the same protocol as for the VH sdAbs whereas SSL7-CT was
expressed with a non-cleavable C-terminal His6-tag and was
therefore only run once through the HisTrap FF column before
SEC. Human C5 was purified from human plasma as previously
described (29).
Detection of Soluble C5b-9 (sC5b-9) and
C5a in Human Serum
Formation of plasma sC5b-9 was measured using an in-
house immunoassay previously described (31). Briefly, for each
measurement point, normal human serum (NHS, with reference
concentration for C5 of 75µg/ml) was activated by incubation
for 4 h at 37◦C in the absence or in the presence of a 1:1 (SSL7-
CT and sdAb_E4, corresponding to a 14-fold molar excess)
or 3:1 (SSL7, 21-fold molar excess) mass ratio of inhibitor.
A few samples of NHS without inhibitor were kept at 4◦C
(“no activation” samples). All samples were then diluted in
PBST containing 10mM EDTA and transferred into a 96-wells
microplate coated with a monoclonal antibody against human
sC5b-9 (Quidel). Following overnight incubation at 4◦C, bound
sC5b-9 was detected with 0.05µg/ml of biotinylated anti-human
C6 antibody (Quidel) for 2 h at room temperature and was
subsequently incubated with 10 ng of Eu3+-labeled streptavidin
(Perkin Elmer) in 100µl of PBST containing 25µMEDTA for 1 h
at room temperature. After wash, bound Europium was detected
by the addition of 200µl of enhancement solution (Perkin Elmer)
and reading of the time-resolved fluorescence on a DELFIA
fluorometer (Victor3, Perkin Elmer) using excitation at 340 nm
and recording of the emission at 615 nm. A standard was made
from NHS activated by incubation with human Ig-Sepharose for
1 h at 37◦C and the concentration of sC5b-9 was quantified by
comparison with recombinant sC5b-9 (Quidel). Wells receiving
only buffer were used to derive a background value that was
subtracted from all sample values.
The concentration of C5a in human serum incubated at
37◦C in the presence or in the absence of C5 inhibitors was
measured by the use of a sandwich-type ELISA kit from Hycult
Biotech (HK349-02). Residual C5a release was estimated from
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samples before activation at 37◦C and this background value was
subtracted to all sample values obtained after activation at 37◦C.
Size Exclusion Chromatography (SEC)
Binding Assay
SEC experiments were performed at 4◦C on a 24ml Superose
6 Increase 10/300 GL column (GE Healthcare) equilibrated in
20mM HEPES pH 7.5, 150mM NaCl. 150 µg of purified C5
were incubated with or without a 10-fold molar excess of purified
sdAb_E4 for 1.5 h at 37◦C before injection onto the SEC column.
A third run was performed with sdAb_E4 alone present in the
same amount as when incubated with C5. For all runs, fractions
corresponding to the position of the C5 peak were analyzed by
SDS-PAGE.
Affinity Measurements Using Microscale
Thermophoresis (MST) and Biolayer
Interferometry (BLI)
Human C5 was fluorescently labeled using the Monolith
NTTMProtein Labeling Kit BLUE-NHS (NanoTemper
technologies) according to the manufacturer’s protocol.
Labeled C5 at a final concentration of 25 nM was incubated
with a dilution series of sdAb_E4 (ranging from 250µM to
7.6 nM) in running buffer (20mMHEPES pH 7.5, 150mMNaCl,
0.1% Tween 20) for 2 h at 37◦C to allow complex formation.
MST measurements were then performed on a Monolith
NT.115 apparatus with samples loaded in standard capillaries
(NanoTemper technologies). Measurements were recorded at
25◦C using the BLUE led at 65% and laser power at 90%. Data
were analyzed in GraphPad Prism and the KD value was derived
from a sigmoidal dose-response fitting model.
BLI measurements were performed at 30◦C on an Octet
RED96 machine (ForteBio) using amine reactive second-
generation (AR2G) biosensors (ForteBio). sdAb_E4-coated
sensors were prepared by dipping the sensors into a solution of
sdAb at 50µg/ml in 10mMNa acetate pH 5.0 for 600 s. Unbound
sdAb was then washed off for 300 s in Buffer A (10mM HEPES
pH 7.5, 150mM NaCl, 0.1% Tween 20) and the baseline was
obtained after 120 s wash in Buffer A. Association with C5 (2-
fold dilution series from 40µM to 312.5 nM in Buffer A) was
performed over 900 s and the dissociation phase in the same
buffer was monitored for 1,800 s. For each point in the dilution
series, binding of C5 in the absence of sdAb_E4 was used as
a reference to subtract the non-specific interactions of C5 with
the biosensor. Curve fitting was performed with GraphPad Prism
using non-linear regression.
Hemolysis Assay on Sheep/Rabbit
Erythrocytes
Sheep and rabbit blood in Alsevers solution were purchased from
SSI Diagnostica. BI buffer was prepared by adding CaCl2 to a final
concentration of 2mM to Veronal Buffer (0.037 mg/ml CaCl2,
0.168mg/mlMgCl2, 8.5mg/ml NaCl, 0.574mg/ml barbitol, 0.374
mg/ml sodium barbitol) from Lonza. GBI buffer corresponded to
BI buffer supplemented with 1 mg/ml gelatin. A final suspension
of 6% RBCs in GBI buffer was prepared from both sheep and
rabbit blood. To allow CP activation, sheep RBCs were pre-
incubated for 30min at room temperature with a solution of
rabbit anti-sheep RBC antibody (Sigma, catalog nr. S1389).
Fifteenµl of NHS were diluted in PBS (final volume 80µl), either
alone or in the presence of increasing amounts of C5 inhibitor
(C5:inhibitor molar ratios ranging from 1:1 to 1:1,000). BI buffer
(120µl) was added and each sample was incubated for 2 h at 37◦C
under gentle agitation. The samples were then aliquoted thrice
in a 96-well microplate with conical V-bottom (Nunc). Each well
received 30µl of RBC suspension and the plate was incubated for
2 h at 37◦C under gentle agitation. The lysis reaction was blocked
by adding 100 µl/well of a cold stop solution (0.9% NaCl, 5mM
EDTA). Cells were spun down at 2,000 rpm at 4◦C for 10min and
the supernatants were transferred into a new 96-well microplate
with flat bottom (Nunc). The absorbance at 405 nm was read
on a VICTOR 3 1420 Multilabel Plate Reader (PerkinElmer).
The reference of 100% hemolysis was extrapolated from samples
in which the RBCs were incubated with NHS in the absence
of inhibitor. For each sample, the final read was obtained from
averaging over the 3 replicate wells and the overall experiment
was done in triplicate.
Bacteriolysis Assay
The bactericidal activity of human serum in the presence of C5
inhibitors was assessed using the BacTiter-GloTMmicrobial cell
viability assay (Promega). Fifteen µl of NHS were incubated
in PBS (final volume 80 µl) either alone or in the presence of
increasing amounts of C5 inhibitor (C5:inhibitor molar ratios
ranging from 1:1 to 1:1,500) for 2 h at 37◦C under gentle
agitation. In each tube was then added 40 µl of a culture of E. coli
DH5α cells grown in LB medium at an 600OD (optical density
at 600 nm) of 0.3. After 2 h of incubation at 37◦C, each sample
was aliquoted thrice in an opaque 96-well microplate (Nunc). An
equivalent volume of BacTiter-GloTM solution was then added
in each well and after 5min. incubation at room temperature,
the luminescence was read on a VICTOR 3 1420 Multilabel Plate
Reader (PerkinElmer). The reference of 100% surviving bacteria
was extrapolated from samples in which the DH5α cells were
incubated with only PBS (no NHS). For each sample, the final
read was obtained from averaging over the 3 replicate wells and
the overall experiment was done in triplicate.
HUVEC Cell Culture and Activation Assay
on HUVEC Apopto-Necrotic Cells
Primary human umbilical vein endothelial cells (HUVEC) were
used for experiments until passage 4 as described previously
(32–34). HUVEC were cultured in M199 medium (containing
1mM HEPES, penicillin (100 U/mL) streptomycin (100 U/mL),
0.2mM L-glutamine) supplemented with 20% FCS, 10% EGM2
(Lonza), 50µg/mL heparin and 10µg/mL ECGS. Spontaneously
detached cells from a confluent HUVEC monolayer after 2–3
days of culture were recovered and their viability was tested by
Annexin-V and DAPI staining. This population consists of a
small proportion of apoptotic and a larger proportion of necrotic
cells and was used for further experiments. Experiments were
performed in M199 medium.
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The HUVEC apopto-necrotic cells were collected by
centrifugation for 5min at 800 g and incubated with increasing
concentrations of different C5 inhibitors diluted in M199.
The cells were then exposed to NHS (AB blood group), as
described previously (35, 36). HUVEC were stained with an
anti-C5b-9 antibody (kindly provided by Prof. Paul Morgan,
Cardiff University) and analyzed by flow cytometry (BD LSR II)
using the FlowJo X software.
Hemolysis Assay on PNH Human
Erythrocytes
The efficacy of the C5 inhibitors was tested on PNH RBCs using
the Ham’s test as adapted from (37). Briefly, fresh RBCs from
a PNH patient were incubated at a final hematocrit of 1% for
1 h with 50% NHS supplemented with MgCl2 at a final 1.5mM
concentration. AP activation was achieved by lowering the pH,
through addition of HCl 1N diluted 1:20 to obtain a final pH
ranging between 6.7 and 6.9. The C5 inhibitors were added to
the tubes at different concentrations before adding NHS. After
1 h of incubation in a water bath at 37◦C under agitation, the
percentage of erythrocyte lysis was determined by recording the
absorbance at 414 nm.
Data Analysis and Statistics
Data analysis and curve fitting were done with GraphPad Prism
version 6.03 forWindows, GraphPad Software, La Jolla California
USA (www.graphpad.com). Statistical analysis was performed in
GraphPad Prism using the Student’s t-test. P-values are as follow:
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.
RESULTS
Selection of a SSL7-Mimicking sdAb by
Phage Display
SSL7 is composed of two functionally independent domains
(25, 38). Our structure of the C5:SSL7 complex revealed that
only the C-terminal β-grasp domain of the protein is required for
C5 binding (25), whereas the N-terminal OB domain mediates
IgA binding (25, 39). Thus, we hypothesized that in order to
obtain an antibody with the same properties as SSL7-CT, i.e.,
selective inhibition of theMAC, we should search for an antibody
recognizing the same epitope as SSL7 on C5. Furthermore,
as our structure of the CVF:C5:SSL7 complex revealed that
SSL7 interacts with cobra venom factor (CVF), we predicted
that with a conventional IgG antibody mimicking SSL7, there
would be a significant risk of interfering with C5 binding to
the C3b or C4b moiety in the C5 convertases mimicked by
CVF in our structure (40). We therefore focused on single-
domain antibodies (around 14 kDa) that are comparable in
size to SSL7-CT. A library of phages displaying humanized
single-domain antibodies corresponding to the variable domain
of the heavy chain (VH sdAbs) was therefore used for the
selection (Figure 1A). Applying our structure-based strategy, we
performed phage display selection on the whole C5 molecule.
However, instead of eluting the bound phages with the often used
trypsin, we performed a competitive elution with recombinant
SSL7-CT. This mode of elution should in principle only displace
phages bearing a sdAb with an epitope on C5 overlapping the
SSL7 epitope. The eluted sdAb-phages were then tested for
direct C5 binding using standard ELISA. Only a small number
of positive clones were obtained, which could be due to the
fact that only a small fraction of the C5-bound sdAb-phages is
displaced by SSL7-CT. Nevertheless, phage dilution series for
the most promising clones were evaluated in the C5 ELISA
(Figure 1B) and the three most affine clones (sdAb_E4, sdAb_F7
and sdAb_G1) were kept for further analysis.
sdAb_E4 Inhibits Soluble C5b-9 Formation
as Well as C5 Cleavage
The three selected sdAbs were prepared as recombinant proteins
in bacteria. We then tested their ability to block the formation
of soluble sC5b-9 in activated human serum. Intact SSL7 and
SSL7-CT were used as controls for sC5b-9 inhibition. The sdAbs
were produced in two different versions: one with a C-terminal
hexahistidine (His6) tag and one without any tag. As shown in
Figure 1C, both versions of sdAb_E4 inhibited sC5b-9 formation
at more than 80% when present at a 14-fold molar excess with
respect to C5. The same level of inhibition was achieved by SSL7-
CT whereas it was slightly lower with SSL7, even at higher molar
excess. The untagged versions of the other sdAbs tested had no
effect on sC5b-9 formation (even at a 42-fold molar excess).
The tagged versions of these two sdAbs seemed to induce a
lower percentage of sC5b-9 assembly perhaps due to unspecific
interaction of the His6 moiety with C5 or a convertase subunit,
but the observed difference with the untagged sdAb_F7 and
sdAb_G1 is statistically not significant. In any case, only sdAb_E4
displayed the desired effect.
To evaluate whether sC5b-9 inhibition exerted by sdAb_E4
was due to general inhibition of C5 cleavage or was more specific,
we measured the release of C5a in activated human serum in
the presence of various C5 inhibitors present at a 15-fold molar
excess as compared to C5. As shown in Figure 1D, both SSL7
and SSL7-CT reduced C5a levels in the serum down to almost
50%. When higher concentrations of inhibitor were used (up
to 750-fold molar excess), C5 cleavage was impaired by 80-90%
by both SSL7 proteins (Supplementary Figure 1). This contrasts
with the previous report suggesting that SSL7-CT was able to
maintain partial C5 cleavage as compared to intact SSL7 (25).
In any case, our selected sdAb acts similarly to SSL7 and SSL7-
CT. Indeed, C5 cleavage inhibition reaches 30% when the sdAb is
present at a 15-fold molar excess (Figure 1D) and the inhibition
increases to 90% at ratios above 1:150 (Supplementary Figure 1).
In conclusion, sdAb_E4 is capable of efficiently preventing MAC
formation while having an effect on C5 cleavage similar to that of
SSL7.
sdAb_E4 Directly Binds C5 in vitro
To ensure that the properties observed for sdAb_E4 are due to a
direct interaction with C5, we then carried out in vitro binding
assays between sdAb_E4 and plasma-purified C5. First, the
formation of a stable complex between the sdAb and its antigen
was evaluated using size exclusion chromatography. Figure 2A
shows the superimposition of the chromatograms obtained for
the two individual components (red and gray curves) and for
Frontiers in Immunology | www.frontiersin.org 5 November 2018 | Volume 9 | Article 2822
Yatime et al. sdAb_E4 Provides MAC Selective Inhibition
FIGURE 1 | Selection of a MAC inhibitor using phage-displayed single-domain antibodies. (A) Structure of the HEL4 domain antibody (26) which constitutes the
scaffold for the Garvan library used for phage display selection with CDR regions highlighted in green, yellow and red. (B) Results of the ELISA evaluating the binding
to C5 of a dilution series of sdAb-displaying phages for the five most promising clones obtained after phage display selection. (C) sC5b-9 assay evaluating the
formation of soluble C5b-9 complex in human serum upon activation at 37◦C, in the absence or in the presence of C5 inhibitors. The presence of a hexahistidine tag
on the sdAbs is indicated in parentheses. The 100% reference is taken from NHS activated in the absence of inhibitor. Data points are averaged over two independent
measurements. (D) C5a assay measuring the amount of C5a released in human serum after activation at 37◦C, in the absence or in the presence of C5 inhibitors. The
100% reference is taken from serum activated in the absence of inhibitor. Measurements were done in duplicates in three independent experiments. P-values:
*p < 0.05; **p < 0.01; ns, difference statistically not significant.
a mix of the two components in which sdAb_E4 is present at
a 10-fold molar excess as compared to C5 (blue curve). The
same amount of sdAb_E4 and C5 was used in the runs for the
individual proteins as compared to the run for the C5:sdAb mix
in order to be able to directly compare the peaks obtained for each
run. No clear shift is observed for the C5 peak when themix is run
on the column. This may be explained by considering that the
molecular weight of a 1:1 C5:sdAb complex (201.7 kDa) is only
slightly higher than that of C5 alone (188.3 kDa). Nevertheless,
SDS-PAGE analysis of the fractions eluting between 15 and
17.5ml (Figure 2B, lanes 5 to 8) reveals that C5 and sdAb_E4
elute together from the column. No band for sdAb_E4 is detected
on the gel when the two components are run individually on the
column (Figure 2B, lanes 3-4 and 9-10). Thus, a stable complex
is formed in vitro between human C5 and sdAb_E4 with an
apparent 1:1 stoichiometry.
The affinity between sdAb_E4 and human C5 was then
measured in solution with microscale thermophoresis, using
labeled C5 and increasing concentrations of unlabeled sdAb_E4.
MST experiments resulted in KD values ranging between 2
and 6µM. A typical experiment is displayed in Figure 2C,
showing a dose-dependent thermophoretic signal with increasing
concentrations of sdAb_E4. Curve fitting with GraphPad Prism
gave a KD value of 3.4± 0.7µM (Figure 2C) for this experiment.
Affinities in the µM range were also measured with biolayer
interferometry (BLI, Supplementary Figure 2). sdAb_E4 was
immobilized on the biosensor tip and a dilution series of C5 was
used as the analyte in solution. Supplementary Figure 2 shows
the BLI curves obtained for a standard experiment. A dose-
dependent response of the sdAb-coated biosensor was observed
in the presence of increasing amounts of C5, revealing binding
of C5 to the biosensor. KD values in the low µM range were
obtained for the different series of measurement performed,
in good agreement with the values obtained with MST. Thus
sdAb_E4 directly binds human C5 in vitro, with a medium
strength affinity.
sdAb_E4 Prevents Erythrocytes Hemolysis
and MAC Deposition on Apopto-Necrotic
Cells
To further analyze the mode of action of sdAb_E4, we
evaluated its effect on complement-mediated lysis of RBCs using
an in vitro hemolysis assay. Sheep erythrocytes activated by
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FIGURE 2 | sdAb_E4 binds human C5 in vitro. (A) Superimposition of the
SEC chromatograms obtained with C5 alone (red curve), sdAb_E4 alone (gray
curve) or a 1:10 molar mix of C5:sdAb (blue curve) on a Superose 6 column.
(B) SDS-PAGE analysis of the fractions corresponding to the first peak (higher
molecular weight species) in the SEC experiments. Fractions 28 and 29 from
all 3 runs were analyzed. The control sample (C) contains purified C5 and
sdAb_E4 in a 1:1 molar ratio. (C) Microscale thermophoresis data obtained for
the binding of sdAb_E4 to labeled C5. sdAb_E4 concentrations are ranging
from 250µM to 7.6 nM (2-fold dilution series). The data points were fitted with
a log(inhibitor) vs. response model using GraphPad Prism. A KD value of
3.4µM was obtained with a quality of the fit R2 = 0.9895.
opsonization with IgG (for testing CP activation) or rabbit
erythrocytes (AP activation) were exposed to NHS pre-activated
at 37◦C in the absence or in the presence of increasing
concentrations of C5 inhibitors. In the absence of inhibitors,
the sheep and rabbit erythrocytes were massively lysed by
NHS (reference value of 100% hemolysis in Figures 3A,B). As
expected, SSL7 and SSL7-CT inhibited CP-mediated hemolysis
by more than 90%, reaching a plateau at a 1:60 molar
ratio as compared to C5 (Figure 3A). sdAb_E4 could also
efficiently block RBC lysis although maximum inhibition
required higher concentrations of sdAb than for the SSL7
proteins (90% inhibition reached at a 1:500 molar ratio,
Figure 3A and Supplementary Figure 3). In contrast, hemolysis
was maintained with sdAb_G1, demonstrating that the observed
inhibitory effect was specific to sdAb_E4. Inhibition of AP-
mediated hemolysis was also achieved by both SSL7, SSL7-
CT and sdAb_E4 whereas sdAb_G1 failed to reduce hemolysis
of rabbit RBCs (Figure 3B). However, AP-inhibition was only
partial as compared to what was observed for the hemolysis
assay on sheep RBCs, suggesting the possibility of a differential
inhibitory effect depending on which complement pathway is
activated.
We then investigated the effect of the anti-C5 sdAb on
complement deposition on endothelial cells. Exposure of apopto-
necrotic HUVEC to NHS induced complement activation until
MAC formation (Figure 3C). Incubation with a 1:12.5 molar
ratio of SSL7 completely inhibited MAC formation whereas the
same amount of SSL7-CT blocked MAC assembly by more than
90%. In the same manner, sdAb_E4 was able to efficiently inhibit
MAC formation and reached the plateau at a 1:25 molar ratio.
On the contrary, sdAb_F7 and sdAb_G1 did not decrease MAC
formation on apopto-necrotic HUVEC even at a 200-fold molar
excess. Taken together these data demonstrate that sdAb_E4
blocks MAC assembly on both endothelial and red blood cells.
sdAb_E4 Maintains Efficient Bacteriolysis
Since our aim was to obtain a C5 inhibitor with selective
properties toward MAC inhibition, we then tested the effect of
sdAb_E4 on complement-mediated bacterial killing of E. coli
DH5α cells. In the absence of inhibitor, human serum completely
lysed the bacterial cells (Figure 3D). As shown previously
(25), SSL7 prevented bacteriolysis in a dose-dependent manner,
reaching a plateau of 80% inhibition at a 1:1,000 molar ratio
with C5 (Figure 3D, red curve). In contrast, SSL7-CT only
partially blocked the bactericidal activity of NHS with a maximal
inhibitory effect of 40% observed at a 1,500-fold molar excess
(Figure 3D, gray curve). Interestingly, sdAb_E4 had almost no
inhibitory effect on complement-mediated bacteriolysis since
bacterial killing remained efficient up to more than 80% at a
C5:sdAb molar ratio of 1:1,500 (Figure 3D, green curve). When
E. coli DH5α cells were incubated with increasing amounts
of sdAb_E4 in the absence of serum, all bacteria survived
(Figure 3D, purple curve), showing that sdAb_E4 itself has no
bacteriolytic activity. The negative control sdAb_G1 had no effect
on bacteriolysis (Figure 3D, blue curve). In conclusion, sdAb_E4
allows complement TP lytic activity on bacterial cells, even at
a high molar excess, therefore proving to be a MAC selective
inhibitor even more efficient than SSL7-CT.
sdAb_E4 may Inhibit Hemolysis of Human
PNH Erythrocytes
Finally, to assess the properties of sdAb_E4 in a set up
more relevant for therapeutic applications, we tested the effect
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FIGURE 3 | sdAb_E4 prevents RBC hemolysis and MAC deposition on endothelial cells but allows efficient bacteriolysis. (A) Hemolysis of sheep RBCs (CP activation)
by human serum in the presence of increasing concentrations of C5 inhibitor. The 100% hemolysis reference is taken from sheep RBCs incubated with human serum
in the absence of inhibitor. Measurements were done in triplicates in three independent experiments. (B) As (A) but the hemolysis assay was performed on rabbit
RBCs (AP activation). (C) MAC formation on apopto-necrotic HUVEC in the presence of increasing concentrations of C5 inhibitor. The 100% reference is taken from
endothelial cells incubated with human serum in the absence of inhibitor. Data were averaged over four independent experiments. (D) Survival of E. coli DH5α cells
upon incubation with activated human serum, in the absence or in the presence of increasing concentrations of C5 inhibitor. The 100% survival reference is taken from
bacterial cells incubated with PBS, in the absence of NHS. Measurements were done in triplicates in three independent experiments. P-values: *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.
of this sdAb on the lysis of human PNH erythrocytes by
complement. Due to limited access to PNH erythrocytes, the
experiment could unfortunately only be performed once. The
results presented here are therefore only indicating a tendency. In
the experiment conducted, exposition of fresh RBCs from a PNH
patient to NHS induced RBC lysis, as measured by the release
of hemoglobin (Figure 4). The presence of SSL7 prevented
complement-mediated hemolysis and reached a plateau at a
molar ratio of 1:12.5 (Figure 4). The residual lysis was in part
due to spontaneous degradation of the RBCs during incubation.
SSL7-CT and sdAb_E4 were also able to prevent complement-
mediated RBC hemolysis (Figure 4), although they did not reach
a plateau at molar ratios of up to 1:50 (Figure 4). Negative
controls sdAb_G1 and sdAb_F7 did not prevent lysis mediated
by complement activation on erythrocytes (Figure 4). These
preliminary data suggest that sdAb_E4 may reduce complement-
mediated lysis of RBCs from PNH patients. However, no firm
conclusion can be drawn on the inhibitory role of sdAb_E4 from
this single experiment and replicates will be necessary to conduct
a more thorough analysis.
DISCUSSION
In this study, we used a pathogen mimicry strategy to achieve
complement specific blockade, through the selection of an SSL7-
like C5 inhibitor. The rationale for selecting such an inhibitor
FIGURE 4 | sdAb_E4 may prevent hemolysis of RBCs from PNH patients.
Hemolysis of PNH erythrocytes by human serum in the presence of increasing
concentrations of C5 inhibitor. The 100% hemolysis reference is taken from
PNH RBCs incubated with human serum in the absence of inhibitor.
Measurement were performed only once due to limited access to PNH
erythrocytes.
was based on conclusions derived from our structures of the
C5:SSL7 and CVF:C5:SSL7 complexes (25, 40). We designed an
antibody phage display protocol and succeeded in selecting a
sdAb which behaved similarly to SSL7 in all our assays and which
displayed specific properties toward the inhibition of TP. Hence,
sdAb_E4 acts as aMAC-specific inhibitor, blocking the formation
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and deposition of the lytic complex on both endothelial cells and
RBCs. Furthermore, we succeeded in reproducing the selectivity
of the inhibition observed with SSL7-CT, i.e., our selected sdAb
blocks CP- and AP-induced hemolysis while preserving almost
completely the bactericidal activity of complement on E. coli
cells, and to an even better extent than SSL7-CT. Although C5
cleavage in the fluid phase was nearly completely prevented
by sdAb_E4 but also by both SSL7 and SSL7-CT (Figure 1D
and Supplementary Figure 1), these molecules allowed partial
C5 cleavage in the context of a pathogen membrane-bound C5
convertase (25). Indeed bactericidal capacity of human serum
was still possible and our previous study on dead S. aureus
showed that SSL7-CT maintained partial cleavage of C5 as
compared to intact SSL7 (25). These results suggest that C5
cleavage in the fluid phase and on host cells surface, which can
induce tissue damage, will be prevented by sdAb_E4, while still
keeping the pathogen destruction capacity. Finally, preliminary
tests on PNH RBCs suggest that our sdAb could prevent
their lysis. Further experiments will however be necessary to
conclude whether sdAb_E4 can efficiently block lysis of PNH
erythrocytes. In any case, our study validates the feasibility of
obtaining a sdAb with selective inhibitory properties toward
complement TP using a structure-based strategy of pathogen
mimicry.
Our sdAb_E4 candidate only displays medium affinity for
human C5, with KD value in the low micromolar range. This
represents a 200-fold lower affinity for C5 as compared to the
model molecule SSL7 (24). Such difference could notably explain
the somewhat distinct performances of the sdAb and SSL7 in
the hemolysis and bacteriolysis assays. As compared to the
C5:eculizumab complex which displays affinity in the 100 pM
range (29, 41), the strength of the C5:sdAb_E4 interaction is
even lower (104 to 105 decrease in affinity). Such low affinity
of sdAb_E4 for C5 as compared to already prescribed drugs
obviously precludes its evaluation in animal disease models or
even in clinical applications. Indeed, we already noticed in our
assays that higher amounts of sdAb_E4 were generally needed
to achieve similar inhibition than that observed with the SSL7
proteins. It is therefore probable that large amounts of sdAb_E4
would also be required in vivo to efficiently block complement
TP. In this context, comparison of the performances of sdAb_E4
and eculizumab in our assays did not appear relevant to us
since the results would be markedly biased by the huge affinity
difference between the two molecules. A more affine sdAb is
required to perform a detailed comparative analysis and to
move on to in vivo studies. Nevertheless, the desired selectivity
has been achieved with our current sdAb and, as such, it
constitutes a promising scaffold for the selection, through affinity
maturation, of an sdAb_E4-derived drug candidate that could
be used in the treatment of complement-mediated hemolytic
disorders.
As for SSL7-CT, the precise mode of action of sdAb_E4
remains unclear. For SSL7, two complementary modes of action
have been proposed. The first one, IgA-dependent, relies on the
simultaneous interaction of SSL7 with both IgA and C5, through
SSL7 N- and C-terminal domains, respectively (25, 39, 40).
This generates a large IgA-SSL72-C52 complex which impairs
convertase binding to its substrate by steric hindrance (25),
thereby annihilating all C5 functions. A second IgA-independent
mechanism which applies for SSL7-CT must also take place,
although its exact nature remains to be determined (25, 39). In
particular, this second mechanism must account for differential
SSL7 effects on bacteriolysis and hemolysis. It has been proposed
that SSL7 on its own may modulate convertase binding to C5
(25). Structural studies of the CVF:C5 complex revealed that
in the presence of SSL7, recognition of C5 by the convertase
is somewhat weakened due to partial disturbance of the
CVF(MG4):C5(MG5) interface by both the β-grasp and OB
domains of the staphylococcal protein (40). A similar effect is
predicted to occur with the endogenous C5 convertases and
could be more pronounced on one or the other C5 convertases
(CP/LP or AP convertase). This hypothesis could explain the
results of our C5a release assay in which SSL7-CT impairs C5a
production to almost the same extent as intact SSL7 (Figure 1D).
In addition, SSL7 may also directly act on MAC inhibition,
downstream of C5 cleavage. SSL7 can bind to C5b, which renders
this hypothesis plausible (25). However, it is unclear whether
the inhibitory effect would be linked to a direct competition
for C5 binding between SSL7 and the C6-C9 proteins forming
the MAC or whether another mechanism is involved. Recent
structures of the C5b-C6 complex did not reveal any overlap
between the SSL7- and C6-binding sites on C5b (42, 43), but
the binding of other MAC components may be hindered by
SSL7, either directly or through allosteric movements. The
recent cryo-electron microscopy map of the MAC refined at a
resolution of 8.5 Å seems to position the two CCP domains
of complement C7 in the cavity delineated by C5 MG1-MG2
and MG5-MG6 domains (44). SSL7 could therefore potentially
interfere with the recruitment of C7 on the C5b-C6 complex.
Finally, regardless of the inhibitory mechanism employed by
SSL7, another possible explanation for its differential inhibition
of hemolysis and bacteriolysis is that MAC assembly on RBCs
and bacterial cells may occur through distinct mechanisms that
would be impaired differentially by the presence of SSL7 (25).
Extrapolation of all these models to our anti-C5 sdAb is
clearly possible since it behaves similarly to SSL7-CT in all the
assays we tested. Thus, as proposed for SSL7, sdAb_E4 may affect
differently C5 convertases binding to their C5 substrate and/or
the formation of MAC on RBCs vs. Gram negative bacteria. The
fact that sdAb_E4 proves to be more potent than SSL7-CT in
maintaining efficient bacteriolysis may be linked to its reduced
affinity for C5 as compared to SSL7 (24), which is also consistent
with the fact that higher concentrations of sdAb_E4 are needed to
reach the same degree of hemolysis inhibition as compared to the
SSL7 fragments (Figures 3A,B). sdAb_E4 may therefore act as a
MAC modulator rather than an inhibitor, which appears to be
advantageous in this context. In the absence of a crystal structure
for the C5:sdAb_E4 complex, we cannot exclude that the binding
epitope of sdAb_E4 on C5 differs from that of SSL7. Our attempts
to crystallize the complex have so far remained unsuccessful,
possibly due to the low affinity of the sdAb for its target. Another
explanation could be the too fast kinetics binding parameters of
the C5:sdAb_E4 interaction, leading to a highly dynamic complex
which tends to dissociate rapidly, thus failing to crystallize. A
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more affine sdAb is probably necessary to conduct such structural
studies and gain detailed insights on the inhibitory mechanism
of sdAb_E4. In this perspective, an immune sdAb library may
have proven more advantageous than the synthetic GARVAN
library we used. Indeed, affinity maturation inherent to in vivo
immunization may have allowed us to obtain sdAbs of much
higher affinities than the ones obtained from a synthetic library.
Obviously, we cannot rule out that sdAb_E4 binds to other
components in human serum, although its mode of selection
(phage display against C5 and elution with SSL7) suggests that
the antibody should be highly specific for the C5 molecule.
More detailed studies are clearly needed to fully characterize
the inhibitory mode of our selected sdAb. On the other hand,
these mechanistic studies will be more informative once a more
affine sdAb candidate has been obtained, the current study only
demonstrating the validity of our drug-design approach.
The effectiveness of C5 inhibition in PNH and aHUS opens
up a gateway for testing this strategy in a large panoply of
other diseases, as diverse as graft rejection, sickle cell disease
or even cancer, where complement contributes to pathogenesis
(22, 34, 45). Our study provides a proof of concept for the
use of SSL7 mimicry as a principle for specific inhibition
of complement, and opens up promising perspectives for the
development of therapeutic molecules targeting complement-
mediated pathologies.
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